The Corona Remedies IPO will issue 61,71,101 shares with a face value of ₹10 per share. It is a mainboard IPO that will raise ₹655.37 crore. Bidding starts on December 8, 2025, and ends on December 10, 2025. The allotment is scheduled on December 11, 2025. The listing on NSE and BSE is set for December 15, 2025.
Corona Remedies IPO has a lot size of 14 shares, with a price range of ₹1008 to ₹1062 per share. The retail investors will have to make a minimum investment of ₹14,868. sNII investors will have to bid for at least 14 lots with ₹2,08,152, whereas bNII investors will invest ₹10,11,024 for 68 lots.
Corona Remedies IPO Details
The following table presents the critical information related to this IPO:
| Particulars | Details |
| Bidding opens on | December 8, 2025 |
| Bidding closes on | December 10, 2025 |
| Price Band | ₹1008 to ₹1062 per share |
| Face value | ₹10 per share |
| Issue price | – |
| IPO Lot Size | 14 Shares |
| Offer for sale | 61,71,101 shares (₹655.37 crore) |
| Fresh issue | – |
| Issue Type | Bookbuilding IPO |
| Listing at | BSE, NSE |
| Total Issue Size | 61,71,101 shares (₹655.37 crore) |
| Minimum Investment | ₹14,868 |
Corona Remedies IPO Timeline
The Corona Remedies IPO will follow the schedule given below:
| Particulars | Details |
| Bidding Opens | December 8, 2025 |
| Bidding Closes | December 10, 2025 |
| Scheduled Allotment | December 11, 2025 |
| Refunds Start From | December 12, 2025 |
| Demat Credit of Shares | December 12, 2025 |
| Expected Listing Date | December 15, 2025 |
| UPI mandate cut-off time | 5 PM on December 10, 2025 |
Corona Remedies Key Performance Indicator
The Corona Remedies Key Performance Indicators (KPIs) are listed below:
| KPIs | FY 2023 | FY 2024 | FY 2025 |
| ROE (%) | 23.29 | 20.36 | 27.50 |
| ROCE (%) | 28.36 | 31.19 | 41.32 |
| Debt Equity (times) | 0.01 | 0.28 | 0.10 |
| RoNW (%) | 20.79 | 18.84 | 24.65 |
| PAT Margin (%) | 9.61 | 8.92 | 12.49 |
| EBITDA margin (%) | 15.27 | 15.89 | 20.55 |
| Price Book Value | – | – | 10.71 |
Corona Remedies Financials
The key financial metrics of Corona Remedies are:
| Particulars (in ₹ million) | 2023 | 2024 | 2025 |
| Revenue | 8,911.01 | 10,209.31 | 12,023.53 |
| Total Asset | 5,950.24 | 8,305.76 | 9,298.61 |
| Profit | 849.29 | 905.03 | 1,494.34 |
Corona Remedies IPO Grey Market Premium
The Corona Remedies IPO Grey Market Premium (GMP) is ₹330 today, reflecting strong interest in the grey market. The premium has shown an upward trend over the past two days, rising from ₹307 to ₹330, which indicates optimistic market sentiment ahead of the listing day.
| Date | GMP (₹) | Estimated Listing Price | Estimated Listing Gain | Trend |
| 04-12-2025 | ₹330 | ₹1392 | 31.07% | Increasing |
| 03-12-2025 | ₹307 | ₹1369 | 28.91% | Increasing |
Note: The GMP values are taken from informal markets and can fluctuate with changes in investor demand, subscription status, and market sentiment.
Corona Remedies IPO Reservation
The IPO shares reservation for each investor category as follows:
| Investor Category | Shares Reservation |
| QIB Shares | Minimum 50% shares |
| NII (HNI) Shares | Maximum 15% shares |
| Retail Shares | Maximum 35% shares |
Lot Size of the Corona Remedies IPO
Investors can apply for the following lot sizes in this IPO:
| Investor Type | No. of Lots | No. of Shares | Amount |
| Individual investors (Minimum) | 1 | 76 | ₹14,868 |
| Individual investors (Maximum) | 13 | 182 | ₹1,93,284 |
| S-HNI (Minimum) | 14 | 196 | ₹2,08,152 |
| S-HNI (Maximum) | 67 | 938 | ₹9,96,156 |
| B-HNI (Minimum) | 68 | 952 | ₹10,11,024 |
Corona Remedies IPO Anchor Investors Details
The details of Corona Remedies ’ IPO Anchor Investors are listed below:
| Particulars | Details |
| Bidding Opens | December 5, 2025 |
| No. of Shares Offered | 60% of the QIB Portion |
| Portion Size | – |
| 50% shares lock-in period (30 Days) | January 10, 2026 |
| Remaining shares lock-in period (90 Days) | March 11, 2026 |
Corona Remedies IPO Prospectus
For additional details, please check the documents given below:
| Draft Red Herring Prospectus (DRHP) | |
| Corona Remedies IPO Anchor Investors | – |
| Red Herring Prospectus (RHP) | |
| Corona Remedies IPO Final Prospectus | Not Disclosed |
About Corona Remedies
Corona Remedies was founded in 2004 and is headquartered in Ahmedabad, Gujarat. It is a pharmaceutical company focusing on specialisations like cardiology, urology, women’s healthcare and pain management. Led by Managing Director Mr. Niravkumar Kirtikumar Mehta, the company has built a strong domestic presence, with over 96% of revenue generated from the Indian market. Its growth is supported by owned manufacturing facilities, an extensive field force, and sustained engagement with healthcare professionals.
The company competes with well-established players such as Torrent Pharmaceuticals, Alkem Laboratories, JB Chemicals, and Mankind Pharma. Corona Remedies continues to strengthen its position in the Indian pharmaceutical market by expanding its product portfolio, enhancing manufacturing capabilities, and adopting data-driven strategies to improve prescription reach and operational efficiency.
| Registrar | Bigshare Services Pvt.Ltd. |
| Lead manager(s) | Kotak Mahindra Capital Co.Ltd.JM Financial Ltd.IIFL Capital Services Ltd. |
Objectives of the Corona Remedies IPO
Since the Corona Remedies IPO is entirely an Offer for Sale (OFS), the company will not receive any proceeds from the issue. As a result, there are no specific objects of the issue, and all funds raised will go to the selling shareholders.
Strength Of Corona Remedies
The following factors contribute to Corona Remedies’ strong position in the market:
1. Rapid Growth
Corona Remedies has been expanding quickly, supported by strong demand in key therapy areas and a growing presence in important healthcare segments.
2. Diversified Portfolio
The company’s portfolio spans women’s health, cardiology, diabetes, urology and pain care, with popular brands like Myoril, B-29, Cor, Tricium and Obimet strengthening its market reach.
3. Nationwide Reach
The company maintains a strong pan-India presence, with a focused strategy targeting specialists in urban and semi-urban markets. This approach enhances doctor relationships and reinforces its position across key therapeutic areas.
4. Experienced Leadership
A capable and experienced leadership team continues to guide the company’s growth, innovation, and long-term strategy.
Risk of Corona Remedies
Corona Remedies is exposed to the risks listed below:
1. Competitive Pressure
The entry of new brands, generics or global players could intensify competition across key therapy areas and reduce market share.
2. Revenue Concentration
A major share of earnings comes from few therapy areas. Any slowdown or competitive pressure in these segments may affect growth.
3. Regulatory & Compliance Risk
The business requires several regulatory approvals and renewals. Delays, lapses or non-compliance could disrupt operations and stability.
4. Geographic Concentration
The revenue is concentrated in major markets such as Maharashtra, Madhya Pradesh, Goa, and Gujarat. Any slowdown, disruption, or competitive pressure in these regions could impact overall financial performance.
Corona Remedies IPO Review
The Corona Remedies IPO offers strong fundamentals backed by consistent revenue growth, expanding margins, and brand growth. The upward-trending GMP reflects positive market expectations ahead of listing. While concentration and regulatory risks exist, the company’s nationwide presence and experienced leadership add confidence. The IPO may attract investors seeking stable growth in India’s pharmaceutical sector.
Other Recent IPO List
You can explore other IPO blogs listed below:
| Neochem Bio IPO | Helloji Holidays IPO |
| Invicta Diagnostic IPO | Vidya Wires IPO |
| Aequs IPO | Milky Mist Dairy Food Ltd. IPO |
| Clear Secured IPO | Meesho IPO |
Corona Remedies IPO FAQs
Corona Remedies IPO is a mainboard IPO. The company is going to raise ₹655.37 crores by issuing 61,71,101 shares.
The Corona Remedies IPO shows strong financial performance and rising GMP, but investors should also consider risks like revenue concentration and regulatory exposure.
With the grey market premium currently at ₹330, the listing return is expected to be around 31.07%.
The Corona Remedies IPO opens on December 8, 2025.
The lot size for the Corona Remedies IPO is 14 shares.
The Corona Remedies IPO can be applied through any supported broker platform using UPI or via the ASBA facility available in your bank account.
The allotment for the Corona Remedies IPO is expected to be finalised on December 11, 2025.
The Corona Remedies IPO is scheduled to list on December 15, 2025, on both BSE and NSE.
